UPDATE: Chardan On Seres Therapeutics Price Target Decrease: Firm Notes No Clinical Differences/Statistical Significance Observed Among Three Treatment Arms Of SER-287 Cohorts; Warns On Mgmt Inability To 'Ascribe Lack Of Efficacy To Any Specific Factors'